RT Journal Article
SR Electronic
T1 Neutrophil proteomics identifies temporal changes and hallmarks of delayed recovery in COVID19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.21.22279031
DO 10.1101/2022.08.21.22279031
A1 Merete B Long
A1 Andrew JM Howden
A1 Holly R Keir
A1 Christina M Rollings
A1 Yan Hui Giam
A1 Thomas Pembridge
A1 Lilia Delgado
A1 Hani Abo-Leyah
A1 Amy F Lloyd
A1 Gabriel Sollberger
A1 Rebecca Hull
A1 Amy Gilmour
A1 Chloe Hughes
A1 Benjamin JM New
A1 Diane Cassidy
A1 Amelia Shoemark
A1 Hollian Richardson
A1 Angus I Lamond
A1 Doreen A Cantrell
A1 James D Chalmers
A1 Alejandro J Brenes
YR 2022
UL http://medrxiv.org/content/early/2022/08/22/2022.08.21.22279031.abstract
AB Rationale Neutrophils are important in the pathophysiology of COVID19 but the molecular changes contributing to altered neutrophil phenotypes following SARS-CoV-2 infection are not fully understood.Objectives To use quantitative mass spectrometry-based proteomics to explore neutrophil phenotypes following acute SARS-CoV-2 infection and during recovery.Methods Prospective observational study of hospitalised patients with PCR-confirmed SARS-CoV-2 infection (May 2020-December 2020). Patients were enrolled within 96 hours of admission, with longitudinal sampling up to 29 days. Control groups comprised non-COVID19 acute lower respiratory tract infection (LRTI) and age-matched non-infected controls. Neutrophils isolated from peripheral blood were processed for mass spectrometry. COVID19 severity and recovery were defined using the WHO ordinal scale.Measurements and Main Results 84 COVID19 patients were included and compared to 91 LRTI patients and 42 controls. 5,800 neutrophil proteins were identified and 1,748 proteins were significantly different (q-value<0.05) in neutrophils from COVID19 patients compared to those of non-infected controls, including a robust interferon response at baseline, which was lost in severe patients one week after enrolment. Neutrophil changes associated with COVID19 disease severity and prolonged illness were characterized and candidate targets for modulation of neutrophil function were identified. Delayed recovery from COVID19 was associated with changes in metabolic and signalling proteins, complement, chemokine and leukotriene receptors, integrins and inhibitory receptors.Conclusions SARS-CoV-2 infection results in the sustained presence of recirculating neutrophils with distinct metabolic profiles and altered capacities to respond to migratory signals and cues from other immune cells, pathogens or cytokines.Scientific Knowledge on the Subject Inflammation is the primary driver of morbidity and mortality in severe COVID19. Type I interferon responses, T-cell exhaustion, cytokine storm, emergency myelopoiesis, myeloid compartment dysregulation and procoagulant pathway activation are well established contributors to COVID19 disease severity. Neutrophils play an important role in COVID19, with elevated neutrophil-to-lymphocyte ratios and the emergence of a circulating immature neutrophil population in individuals with severe symptoms. Neutrophil infiltration in the lungs coupled with the release of neutrophil extracellular traps has also been reported in severe and fatal COVID19. The aim of this study was to quantitatively map the proteomes of peripheral blood neutrophils from a cohort of hospitalised COVID19 patients to understand how SARS-CoV-2 infection changes neutrophil phenotypes and functional capacity.What this study adds to the field High-resolution mass spectrometry was used to characterise the proteomes of peripheral blood neutrophils from >200 individuals at different stages of disease. This work has comprehensively mapped neutrophil molecular changes associated with mild and severe COVID19 and identified significant quantitative changes in more than 1700 proteins in neutrophils from patients hospitalised with COVID19 versus patients with non-COVID19 acute respiratory infections. The study identifies neutrophil protein signatures associated with COVID19 disease severity. The data also show that alterations in neutrophil proteomes can persist in fully recovered patients and identify distinct neutrophil proteomes in recovered versus non recovered patients. Our study provides novel insights into neutrophil responses during acute COVID19 and reveals that altered neutrophil phenotypes persist in convalescent COVID19 patients.Competing Interest StatementJames D. Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Novartis and Insmed; and received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis and Zambon.Funding StatementThis work was funded by the Chief Scientist Office Rapid Response COVID19 Research Grant (COV/DUND/20/01) and the UK Coronavirus Immunology Consortium (MR/V028448) and the Wellcome Trust (205023/Z/16/Z). DAC is supported by a Wellcome Trust Principal Research fellowship (097418/Z/11/Z). JDC is supported by the GSK/Asthma and Lung UK Chair of Respiratory Research (C17-2) and a Scottish Senior Fellowship from the Chief Scientist Office (SCAF17/03).   Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The East of Scotland Research Ethics Committee gave ethical approval for this work (reference number 20/ES/0055)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the mass spectrometry files, as well as the processed search result files are available at PRIDE